TOSS, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.877
AS - Asia 8.275
EU - Europa 5.854
SA - Sud America 1.386
AF - Africa 264
OC - Oceania 56
Continente sconosciuto - Info sul continente non disponibili 11
Totale 28.723
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.576
SG - Singapore 2.490
CN - Cina 2.007
IT - Italia 1.466
GB - Regno Unito 1.123
VN - Vietnam 1.099
BR - Brasile 1.027
HK - Hong Kong 1.016
DE - Germania 582
SE - Svezia 576
FI - Finlandia 354
IE - Irlanda 343
RU - Federazione Russa 318
KR - Corea 277
FR - Francia 275
IN - India 246
ID - Indonesia 195
CA - Canada 130
TR - Turchia 129
UA - Ucraina 126
BD - Bangladesh 123
AR - Argentina 120
MX - Messico 113
NL - Olanda 105
IQ - Iraq 103
JP - Giappone 100
BG - Bulgaria 98
ES - Italia 79
PL - Polonia 71
ZA - Sudafrica 69
CO - Colombia 59
PK - Pakistan 58
EC - Ecuador 57
AU - Australia 51
MY - Malesia 51
EG - Egitto 49
AT - Austria 45
TW - Taiwan 45
LT - Lituania 44
AE - Emirati Arabi Uniti 42
MA - Marocco 36
VE - Venezuela 36
SA - Arabia Saudita 32
IR - Iran 31
CL - Cile 30
PH - Filippine 30
UZ - Uzbekistan 27
KE - Kenya 26
BE - Belgio 25
PY - Paraguay 24
NO - Norvegia 23
JO - Giordania 21
CZ - Repubblica Ceca 20
NP - Nepal 17
TH - Thailandia 17
AZ - Azerbaigian 16
DK - Danimarca 16
GR - Grecia 15
HU - Ungheria 15
MD - Moldavia 15
SI - Slovenia 15
TN - Tunisia 15
BO - Bolivia 13
IL - Israele 13
CH - Svizzera 12
DZ - Algeria 12
PA - Panama 12
RO - Romania 12
AL - Albania 11
DO - Repubblica Dominicana 10
HR - Croazia 10
KZ - Kazakistan 10
PE - Perù 10
SY - Repubblica araba siriana 10
KG - Kirghizistan 9
LB - Libano 9
OM - Oman 9
RS - Serbia 9
BY - Bielorussia 8
CR - Costa Rica 8
LV - Lettonia 8
PT - Portogallo 8
UY - Uruguay 8
CI - Costa d'Avorio 7
CY - Cipro 7
ET - Etiopia 7
JM - Giamaica 7
MK - Macedonia 7
MT - Malta 7
AO - Angola 6
BH - Bahrain 6
GE - Georgia 6
SN - Senegal 6
EU - Europa 5
GH - Ghana 5
NZ - Nuova Zelanda 5
XK - ???statistics.table.value.countryCode.XK??? 5
CG - Congo 4
HN - Honduras 4
PS - Palestinian Territory 4
Totale 28.648
Salva come PNG Salva come JPEG
Città #
Ashburn 1.539
Singapore 1.441
Santa Clara 1.367
Fairfield 1.185
Hong Kong 986
Chandler 777
Hefei 685
San Jose 572
Woodbridge 561
Seattle 496
Houston 442
Cambridge 403
Southend 402
Beijing 360
Ho Chi Minh City 353
Wilmington 350
Nyköping 349
London 346
Dublin 338
Helsinki 282
Los Angeles 262
Dallas 260
Seoul 258
Council Bluffs 256
Hanoi 253
New York 226
Ann Arbor 215
Dearborn 211
Modena 201
The Dalles 169
Chicago 159
Jakarta 140
Lauterbourg 130
San Diego 111
Jacksonville 105
Bologna 103
Milan 100
Princeton 100
São Paulo 99
Sofia 95
Moscow 93
Munich 90
Shanghai 79
Tokyo 79
Frankfurt am Main 76
Orem 68
Salt Lake City 68
Bremen 59
Buffalo 59
Rome 58
Da Nang 53
Warsaw 53
Eugene 52
Izmir 52
Redwood City 52
Baghdad 51
Haiphong 50
Fremont 44
Manchester 42
Reggio Emilia 41
Dong Ket 40
Kent 40
Nuremberg 40
Guangzhou 36
Johannesburg 36
Montreal 36
Phoenix 36
Rio de Janeiro 36
Mexico City 34
Chennai 33
Redondo Beach 32
Belo Horizonte 31
Brooklyn 31
Lappeenranta 31
Mumbai 31
Portsmouth 31
Stockholm 31
Columbus 30
Denver 30
Parma 30
Atlanta 28
Düsseldorf 28
Falls Church 28
San Giuliano Milanese 28
Dhaka 27
Poplar 27
Toronto 26
Turku 26
Madrid 25
Sydney 25
Vienna 24
Amsterdam 23
Brasília 23
Elk Grove Village 23
Tashkent 23
Boston 22
Florence 22
Lawrence 22
Nairobi 22
Tampa 22
Totale 19.075
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 591
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 466
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 457
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 441
Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: Hybrid Posters 395
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 376
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 370
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 368
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 354
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 333
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 331
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 320
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 319
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 318
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 314
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 297
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 295
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 292
NUT midline carcinoma of the head and neck: current perspectives 289
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 288
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 286
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 282
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 281
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 280
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 278
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 272
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 272
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 271
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 271
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers 270
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 266
Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study 264
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 263
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 261
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 258
Combined hormonal contraceptives in BRCA gene mutation carriers: why not? 256
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 251
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 249
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 246
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 243
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 242
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 241
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 241
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 240
Male mammary myofibroblastoma: Two case reports and brief review of literature 237
Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which? 236
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 230
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores 230
Chemoprevention strategies for high risk women 230
Characterization of new ATM deletion associated with hereditary breast cancer 229
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 228
Twenty-years experience with de novo metastatic breast cancer 227
The role of exosomes in breast cancer diagnosis 227
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 225
The generally low sensitivity of CA125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype 224
Relative and disease-free survival for breast cancer in relation to subtype: a population-based study 222
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 222
Hereditary ovarian cancers: State of the art 221
Male Bilateral Risk-Reducing Mastectomy: Report of a Case 218
Breast ultrasound in high-risk women 214
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification 214
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 214
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 214
BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study 212
BRCA mutation carriers’ perception about benefits and risks associated with combined hormonal contraceptives use 210
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness 209
Radiological screening programs for women at high risk of developing breast cancer 208
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 207
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis 207
Molecular characterization and targeted therapeutic approaches in breast cancer 205
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 204
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 199
Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study 199
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial 194
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes 191
PARP inhibitors for the treatment of ovarian cancer 189
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 184
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 182
Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk 179
Management of PALB2-associated breast cancer: A literature review and case report 179
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 179
Personalized Systemic Therapies in Hereditary Cancer Syndromes 178
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 177
COVID-related disruption in mammographic screening: a year later. 175
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles 175
Occult breast cancer: the uncommon presentation of a common disease 172
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report 169
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 169
Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less 166
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees 165
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 159
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 159
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores 159
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 158
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 158
LOW-FREQUENCY ALLELE VARIANTS IN NGS MULTI-GENE PANELS FOR HEREDITARY CANCER TESTING: ARTIFACTS, CHIP OR MOSAICS? MANAGING THE RESULTS IN THE LABORATORY ROUTINE 153
Breast cancer screening of mutation carriers in the era of COVID-19 pandemic 153
Automation of a capture-based NGS workflow: one thousand patients experience in a diagnostic clinical routine framework 150
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group 147
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer 146
Totale 24.385
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.352
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.352
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021677 0 0 0 0 0 0 0 0 0 234 225 218
2021/20221.999 141 173 144 82 72 147 94 109 265 173 355 244
2022/20232.486 279 310 172 201 231 275 51 184 541 40 101 101
2023/20241.828 93 96 99 186 277 148 244 237 68 74 115 191
2024/20256.202 145 59 124 324 1.039 805 599 383 737 407 668 912
2025/202611.189 931 501 1.161 1.442 1.551 871 1.621 730 1.285 1.096 0 0
Totale 28.984